iScience (Jun 2020)

Integrating Systems Biology and an Ex Vivo Human Tumor Model Elucidates PD-1 Blockade Response Dynamics

  • Munisha Smalley,
  • Michelle Przedborski,
  • Saravanan Thiyagarajan,
  • Moriah Pellowe,
  • Amit Verma,
  • Nilesh Brijwani,
  • Debika Datta,
  • Misti Jain,
  • Basavaraja U. Shanthappa,
  • Vidushi Kapoor,
  • Kodaganur S. Gopinath,
  • D.C. Doval,
  • K.S. Sabitha,
  • Gaspar Taroncher-Oldenburg,
  • Biswanath Majumder,
  • Pradip Majumder,
  • Mohammad Kohandel,
  • Aaron Goldman

Journal volume & issue
Vol. 23, no. 6
p. 101229

Abstract

Read online

Summary: Ex vivo human tumor models have emerged as promising, yet complex tools to study cancer immunotherapy response dynamics. Here, we present a strategy that integrates empirical data from an ex vivo human system with computational models to interpret the response dynamics of a clinically prescribed PD-1 inhibitor, nivolumab, in head and neck squamous cell carcinoma (HNSCC) biopsies (N = 50). Using biological assays, we show that drug-induced variance stratifies samples by T helper type 1 (Th1)-related pathways. We then built a systems biology network and mathematical framework of local and global sensitivity analyses to simulate and estimate antitumor phenotypes, which implicate a dynamic role for the induction of Th1-related cytokines and T cell proliferation patterns. Together, we describe a multi-disciplinary strategy to analyze and interpret the response dynamics of PD-1 blockade using heterogeneous ex vivo data and in silico simulations, which could provide researchers a powerful toolset to interrogate immune checkpoint inhibitors.

Keywords